| John Michael Porter, OT | |
|
103 Medical Park, Hattiesburg, MS 39401-9042 | |
| (601) 268-5757 | |
| (601) 579-5220 |
| Full Name | John Michael Porter |
|---|---|
| Gender | Male |
| Speciality | Occupational Therapy |
| Experience | 9 Years |
| Location | 103 Medical Park, Hattiesburg, Mississippi |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1518347681 | NPI | - | NPPES |
| 08425764 | Medicaid | MS |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225X00000X | Occupational Therapist | (* (Not Available)) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Hattiesburg Clinic, Pa | 5193706794 | 489 |
News Archive
Despite continued reports of economic growth in Africa, much of the continent remains wracked by poverty, with roughly one in five citizens saying they frequently lack food, clean water and medical care, according to the largest survey of African citizens.
WellCare Health Plans, Inc. today reported results for the three and six months ended June 30, 2010. As determined under generally accepted accounting principles, the Company reported a second quarter 2010 net loss of $128.9 million, or $3.05 per diluted share, compared with net income of $37.0 million, or $0.88 per diluted share, for the prior year period.
As the effectiveness of anesthesia, pain management and rehabilitation continues to improve, more orthopaedic procedures are being done on an outpatient basis. In a new research study presented today at the 2014 Annual Meeting of the American Academy of Orthopaedic Surgeons, same-day total joint replacement (TJR) patient outcomes were comparable to those of patients admitted to the hospital and staying at least one night following surgery.
Patients with metastatic melanoma taking the recently approved drug vemurafenib (Zelboraf) responded well to the twice daily pill, but some of them developed a different, secondary skin cancer.
Seattle Genetics, Inc. and Millennium Pharmaceuticals, Inc.: The Takeda Oncology Company today announced that they have initiated a phase I clinical trial of brentuximab vedotin (SGN-35) in combination with chemotherapy for the treatment of newly diagnosed Hodgkin lymphoma patients. Brentuximab vedotin is an antibody-drug conjugate (ADC) that is also in single-agent clinical trials, including a pivotal trial for relapsed and refractory Hodgkin lymphoma and a phase II trial for systemic anaplastic large cell lymphoma.
› Verified 1 days ago
| Provider Name | Hattiesburg Clinic Pa |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1740213446 PECOS PAC ID: 5193706794 Enrollment ID: O20040528000685 |
News Archive
Despite continued reports of economic growth in Africa, much of the continent remains wracked by poverty, with roughly one in five citizens saying they frequently lack food, clean water and medical care, according to the largest survey of African citizens.
WellCare Health Plans, Inc. today reported results for the three and six months ended June 30, 2010. As determined under generally accepted accounting principles, the Company reported a second quarter 2010 net loss of $128.9 million, or $3.05 per diluted share, compared with net income of $37.0 million, or $0.88 per diluted share, for the prior year period.
As the effectiveness of anesthesia, pain management and rehabilitation continues to improve, more orthopaedic procedures are being done on an outpatient basis. In a new research study presented today at the 2014 Annual Meeting of the American Academy of Orthopaedic Surgeons, same-day total joint replacement (TJR) patient outcomes were comparable to those of patients admitted to the hospital and staying at least one night following surgery.
Patients with metastatic melanoma taking the recently approved drug vemurafenib (Zelboraf) responded well to the twice daily pill, but some of them developed a different, secondary skin cancer.
Seattle Genetics, Inc. and Millennium Pharmaceuticals, Inc.: The Takeda Oncology Company today announced that they have initiated a phase I clinical trial of brentuximab vedotin (SGN-35) in combination with chemotherapy for the treatment of newly diagnosed Hodgkin lymphoma patients. Brentuximab vedotin is an antibody-drug conjugate (ADC) that is also in single-agent clinical trials, including a pivotal trial for relapsed and refractory Hodgkin lymphoma and a phase II trial for systemic anaplastic large cell lymphoma.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John Michael Porter, OT 415 S 28th Ave, Hattiesburg, MS 39401-7246 Ph: (601) 268-5757 | John Michael Porter, OT 103 Medical Park, Hattiesburg, MS 39401-9042 Ph: (601) 268-5757 |
News Archive
Despite continued reports of economic growth in Africa, much of the continent remains wracked by poverty, with roughly one in five citizens saying they frequently lack food, clean water and medical care, according to the largest survey of African citizens.
WellCare Health Plans, Inc. today reported results for the three and six months ended June 30, 2010. As determined under generally accepted accounting principles, the Company reported a second quarter 2010 net loss of $128.9 million, or $3.05 per diluted share, compared with net income of $37.0 million, or $0.88 per diluted share, for the prior year period.
As the effectiveness of anesthesia, pain management and rehabilitation continues to improve, more orthopaedic procedures are being done on an outpatient basis. In a new research study presented today at the 2014 Annual Meeting of the American Academy of Orthopaedic Surgeons, same-day total joint replacement (TJR) patient outcomes were comparable to those of patients admitted to the hospital and staying at least one night following surgery.
Patients with metastatic melanoma taking the recently approved drug vemurafenib (Zelboraf) responded well to the twice daily pill, but some of them developed a different, secondary skin cancer.
Seattle Genetics, Inc. and Millennium Pharmaceuticals, Inc.: The Takeda Oncology Company today announced that they have initiated a phase I clinical trial of brentuximab vedotin (SGN-35) in combination with chemotherapy for the treatment of newly diagnosed Hodgkin lymphoma patients. Brentuximab vedotin is an antibody-drug conjugate (ADC) that is also in single-agent clinical trials, including a pivotal trial for relapsed and refractory Hodgkin lymphoma and a phase II trial for systemic anaplastic large cell lymphoma.
› Verified 1 days ago
Jessica Kopf Cornett, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 10 Medical Blvd, Hattiesburg, MS 39401 Phone: 601-264-0310 | |
Jeremy Lofton, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 103 Fox Chase Dr, Hattiesburg, MS 39402 Phone: 601-366-1081 | |
Carly Toups, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 103 Fox Chase Dr, Hattiesburg, MS 39402 Phone: 601-366-1081 | |
Lee Pace, FNP, OTR Occupational Therapist Medicare: Medicare Enrolled Practice Location: 6051 U S Highway 49, Hattiesburg, MS 39401 Phone: 601-288-7000 | |
Alicia Thornton, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 103 Fox Chase Dr, Hattiesburg, MS 39402 Phone: 601-366-1081 Fax: 601-607-1377 | |
Kellie Sasser, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 10 Medical Blvd, Hattiesburg, MS 39401 Phone: 601-543-0310 | |
Naja Walton, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 103 Fox Chase Dr, Hattiesburg, MS 39402 Phone: 601-366-1081 |